Galena Biopharma, Inc. Press Releases

GALE 
$1.53
*  
0.04
2.68%
Get GALE Alerts
*Delayed - data as of Dec. 26, 2014  -  Find a broker to begin trading GALE now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    GALE After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
Galena Biopharma Presents HER2 Screening Data Including Preliminary Leica Bond Oracle(TM) Results From the Phase 3 NeuVax(TM) (nelipepimut-S) Clinical Trial at the 2014 San Antonio Breast Cancer Symposium (SABCS)
12/11/2014 8:35:00 AM - GlobeNewswire


Galena Biopharma Presents GALE-401 (Anagrelide Controlled Release) Clinical Trial Data at the 56th American Society of Hematology (ASH) Annual Meeting & Exposition
12/8/2014 7:05:00 AM - GlobeNewswire


Galena Biopharma to Present HER2 Screening Data From the Phase 3 NeuVax(TM) (nelipepimut-S) Clinical Trial at the 2014 San Antonio Breast Cancer Symposium (SABCS)
12/5/2014 7:05:00 AM - GlobeNewswire


Galena Biopharma Receives Notice of Allowance of U.S. Patent Application for GALE-401 (Anagrelide Controlled Release) Composition of Matter
12/2/2014 7:05:00 AM - GlobeNewswire


Galena Biopharma to Present GALE-401 (Anagrelide Controlled Release) Phase 1 Clinical Trial Data at the 56th American Society of Hematology (ASH) Annual Meeting & Exposition
12/1/2014 7:05:00 AM - GlobeNewswire


Galena Biopharma to Present GALE-401 (Anagrelide Controlled Release) Phase 1 Clinical Trial Data at the 56th American Society of Hematology (ASH) Annual Meeting & Exposition
12/1/2014 7:05:00 AM - GlobeNewswire


Galena Biopharma to Present at the Oppenheimer 25th Annual Healthcare Conference
11/25/2014 7:05:00 AM - GlobeNewswire


Galena Biopharma Announces Purchase Agreement for Up to $55.0 Million With Lincoln Park Capital Fund, LLC
11/20/2014 4:20:00 PM - GlobeNewswire


Galena Biopharma Completes Enrollment in GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial
11/18/2014 7:05:00 AM - GlobeNewswire


Galena Biopharma to Present at the Stifel 2014 Healthcare Conference
11/13/2014 7:05:00 AM - GlobeNewswire


Galena Biopharma Doses First Patient in Phase 2 Clinical Trial With NeuVax(TM) (nelipepimut-S) in Combination With Herceptin(R) (trastuzumab) to Treat High-Risk HER2 3+ or HER2 Gene-Amplified Breast Cancer Patients
11/11/2014 7:05:00 AM - GlobeNewswire


Galena Biopharma Doses First Patient in Phase 2 Clinical Trial With NeuVax(TM) (nelipepimut-S) in Combination With Herceptin(R) (trastuzumab) to Treat High-Risk HER2 3+ or HER2 Gene-Amplified Breast Cancer Patients
11/11/2014 7:05:00 AM - GlobeNewswire


Galena Biopharma Presents GALE-301 (Folate Binding Protein Immunotherapy) Phase 2a Clinical Trial Data at the Society for Immunotherapy of Cancer (SITC) 29th Annual Meeting
11/7/2014 7:05:00 AM - GlobeNewswire


Galena Biopharma to Present GALE-301 (Folate Binding Protein) Phase 2a Clinical Trial Data at the Society for the Immunotherapy of Cancer (SITC) 29th Annual Meeting on Friday, November 7, 2014
11/4/2014 7:05:00 AM - GlobeNewswire


Galena Biopharma Reports Third Quarter 2014 Results
11/3/2014 4:20:00 PM - GlobeNewswire


Galena Biopharma to Report Third Quarter 2014 Financial Results on Monday, November 3, 2014
10/27/2014 7:05:00 AM - GlobeNewswire


Galena Biopharma Receives Notice of Allowance of Improvement Patent for NeuVax(TM) (nelipepimut-S) in Japan
10/14/2014 7:05:00 AM - GlobeNewswire


Galena Biopharma Announces Notice of Allowance of U.S. Patent Application for NeuVax(TM) (nelipepimut-S) Combination
10/8/2014 7:05:00 AM - GlobeNewswire